Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 13/20 | 0.52 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 4/20 | 0.46 |
| ▸ | IKZF2 | Q9UKS7 | 5/20 | 0.45 |
| ▸ | GSPT1 | P15170 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | WIZ | O95785 | 1/20 | 0.44 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.43 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30985233 | 1.00 | CRBN (0.52) | CRBNCSNK1A1DDB1IKZF2GSPT1 | |
| SCHEMBL31727669 | 1.00 | CRBN (0.52) | CRBNCSNK1A1DDB1IKZF2GSPT1 | |
| SCHEMBL27092903 | 0.96 | CRBN (0.49) | CRBNCSNK1A1DDB1IKZF2GSPT1 | |
| SCHEMBL30984991 | 0.96 | CRBN (0.51) | CRBNCSNK1A1DDB1IKZF2GSPT1 | |
| SCHEMBL31726811 | 0.94 | CRBN (0.52) | CRBNCSNK1A1DDB1IKZF2GSPT1 | |
| SCHEMBL22498388 | 0.94 | CRBN (0.52) | CRBNCSNK1A1DDB1IKZF2GSPT1 | |
| SCHEMBL24571664 | 0.93 | CRBN (0.52) | CRBNCSNK1A1DDB1IKZF2GSPT1 | |
| SCHEMBL22291534 | 0.93 | CRBN (0.52) | CRBNDDB1GSPT1 | |
| SCHEMBL29913936 | 0.93 | CRBN (0.52) | CRBNDDB1GSPT1 | |
| SCHEMBL30984958 | 0.93 | CRBN (0.51) | CRBNCSNK1A1DDB1IKZF2GSPT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220388984-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2022-12-08 | — | — | US | disclosed |
| US-11117885-B2 | Compounds having estrogen receptor alpha degradation activity and uses thereof | ACCUTAR BIOTECHNOLOGY INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20210139458-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2021-05-13 | — | — | US | disclosed |
| WO-2020211822-A1 | A CLASS OF BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUNDS FOR TARGETED DEGRADATION OF ANDROGEN RECEPTORS AND USE THEREOF | 成都海创药业有限公司 | 2020-10-22 | — | — | WO | disclosed |
| US-20200299264-A1 | COMPOUNDS HAVING ESTROGEN RECEPTOR ALPHA DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2020-09-24 | — | — | US | disclosed |
| US-10696659-B2 | Compounds having estrogen receptor alpha degradation activity and uses thereof | ACCUTAR BIOTECHNOLOGY INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20200157078-A1 | NOVEL COMPOUNDS HAVING ESTROGEN RECEPTOR ALPHA DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2020-05-21 | — | — | US | disclosed |
| US-10647698-B2 | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders | ARVINAS OPERATIONS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20180155322-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2018-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11117885-B2 | Compounds having estrogen receptor alpha degradation activity and uses thereof | ESR2, ESRRG, ESR1 | CRBN 2181/4885CSNK1A1 155/4885DDB1 2127/4885 |
| US-20210139458-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | MDM2, CRBN, VHL | CRBN 2/4885CSNK1A1 688/4885DDB1 192/4885 |
| US-20220388984-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | MDM2, CRBN, VHL | CRBN 2/4885CSNK1A1 688/4885DDB1 192/4885 |
| US-20200157078-A1 | NOVEL COMPOUNDS HAVING ESTROGEN RECEPTOR ALPHA DEGRADATION ACTIVITY AND USES THEREOF | ESR2, ESRRG, ESR1 | CRBN 2038/4885CSNK1A1 161/4885DDB1 1860/4885 |
| US-20200299264-A1 | COMPOUNDS HAVING ESTROGEN RECEPTOR ALPHA DEGRADATION ACTIVITY AND USES THEREOF | ESR2, ESRRG, ESR1 | CRBN 2181/4885CSNK1A1 155/4885DDB1 2127/4885 |
| US-20180155322-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | MDM2, CRBN, VHL | CRBN 2/4885CSNK1A1 688/4885DDB1 192/4885 |
| US-10696659-B2 | Compounds having estrogen receptor alpha degradation activity and uses thereof | ESR2, ESRRG, ESR1 | CRBN 2181/4885CSNK1A1 155/4885DDB1 2127/4885 |
| US-10647698-B2 | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders | MDM2, CRBN, VHL | CRBN 2/4885CSNK1A1 688/4885DDB1 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.